China's stem cell technology benefits international patients, giving type 2 diabetes patients new hope for health.

Mr. B (pseudonym), a Morocco patient in his fifties , had been suffering from type 2 diabetes for over ten years. Due to long-term blood sugar fluctuations, he had developed early signs of diabetic complications such as abnormal kidney and liver function indicators, and conventional drug treatments were insufficient to effectively curb the progression of his disease. After learning about China's advanced stem cell therapy technology and clinical achievements in diabetes, Harbor Health assisted Mr. B in coming to China to seek a more targeted and innovative treatment plan.

Case Overview

Mr. B (pseudonym), a Morocco patient in his fifties , had been suffering from type 2 diabetes for over ten years. Due to long-term blood sugar fluctuations, he had developed early signs of diabetic complications such as abnormal kidney and liver function indicators, and conventional drug treatments were insufficient to effectively curb the progression of his disease. After learning about China's advanced stem cell therapy technology and clinical achievements in diabetes, Harbor Health assisted Mr. B in coming to China to seek a more targeted and innovative treatment plan.

Cause & Challenge

Upon admission, the medical team first conducted a comprehensive physical examination and systematic evaluation for Mr. B. Through multi-dimensional examinations, it was determined that he met the indications for stem cell therapy for diabetes. At the same time, contraindications such as tumor risk , active infection, and coagulation dysfunction were strictly ruled out, laying a solid foundation for treatment safety. Taking into account Mr. B's weight, physical function, and the characteristics of his condition, the medical team customized a personalized cell preparation plan for him, using advanced cell culture and screening technologies to ensure that the prepared stem cells were of high purity and strong activity, precisely suited to his treatment needs. Unlike traditional diabetes treatments, Mr. B's stem cell therapy was convenient and highly effective throughout, requiring no hospitalization. A single course of treatment consisted of only three stem cell infusions. The infusion process was gentle and caused minimal discomfort, minimizing the impact of the treatment on his daily life. Simultaneously , Harbor Health quickly assembled a dedicated health management team to provide comprehensive and close monitoring of Mr. B's blood sugar levels, medication use, diet, and exercise habits after the stem cell infusion. Regular monitoring of changes in these indicators allowed for timely adjustments to his medication regimen and lifestyle guidance, ensuring the treatment's effects were steadily observed.

Why China

Harbor Health connected the patient with appropriate Chinese medical resources, coordinated expert review, hospital access, interpretation, and treatment planning based on the case needs.

Treatment & Benefits

Stem cell therapy reduced medication burden and improved glucose control.

Full Story

Upon admission, the medical team first conducted a comprehensive physical examination and systematic evaluation for Mr. B. Through multi-dimensional examinations, it was determined that he met the indications for stem cell therapy for diabetes. At the same time, contraindications such as tumor risk , active infection, and coagulation dysfunction were strictly ruled out, laying a solid foundation for treatment safety. Taking into account Mr. B's weight, physical function, and the characteristics of his condition, the medical team customized a personalized cell preparation plan for him, using advanced cell culture and screening technologies to ensure that the prepared stem cells were of high purity and strong activity, precisely suited to his treatment needs.

Unlike traditional diabetes treatments, Mr. B's stem cell therapy was convenient and highly effective throughout, requiring no hospitalization. A single course of treatment consisted of only three stem cell infusions. The infusion process was gentle and caused minimal discomfort, minimizing the impact of the treatment on his daily life. Simultaneously , Harbor Health quickly assembled a dedicated health management team to provide comprehensive and close monitoring of Mr. B's blood sugar levels, medication use, diet, and exercise habits after the stem cell infusion. Regular monitoring of changes in these indicators allowed for timely adjustments to his medication regimen and lifestyle guidance, ensuring the treatment's effects were steadily observed.

After three months of standardized follow-up, Mr. B's treatment results exceeded expectations: the dosage of hypoglycemic drugs that originally needed to be taken long-term was significantly reduced, fasting blood glucose and postprandial blood glucose were both controlled within a reasonable range, previously abnormal kidney and liver indicators gradually returned to normal, and the risk of developing diabetic complications was effectively controlled.

Mr. B's successful treatment case is a microcosm of the continuous breakthroughs in stem cell research and application in China. Chinese scientists have not only achieved a functional cure for type 1 diabetes using stem cell regeneration therapy for the first time, with related findings published in the internationally renowned journal “Cell”, but have also successfully developed the world's second allogeneic universal regenerated islet product, breaking the bottleneck of the shortage of traditional islet transplant donors. In terms of technological innovation, Chinese research teams have overcome the core technology of chemically reprogrammed induced pluripotent stem cells, opening up a completely new route for the preparation of human pluripotent stem cells. This technology won the 2025 Future Science Prize in Life Sciences. Simultaneously, breakthroughs in areas such as stem cell directed differentiation and microencapsulation technology have made stem cell therapy more precise and safer. Its low immunogenicity significantly reduces the risk of rejection, providing more reliable technical support for clinical applications. Currently, China has established a comprehensive stem cell clinical research system and regulatory framework, achieving standardization and normalization of the entire process from cell preparation and clinical treatment to postoperative management.

So, which diabetic patients are suitable for stem cell therapy? Based on clinical practice and industry standards, the primary candidates are type 2 diabetic patients with a long disease course and poor response to conventional drug treatment, especially those with potential or early-stage complications such as kidney or neurological problems, like Mr. B. Stem cells can repair damaged tissues through paracrine effects, improve insulin resistance, and reduce the risk of complications. It is important to note that stem cell therapy is not suitable for all diabetic patients; there are clear contraindications, and a professional medical team must be consulted for evaluation .